Eniluracil

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Eniluracil 是一种口服活性二氢嘧啶脱氢酶 (DPD) 抑制剂，可将 5-FU 的口服生物利用度提高至 100%，促进均匀吸收和可预测的毒性。

Eniluracil is an orally activedihydropyrimidine dehydrogenase (DPD) inhibitorincreases the oral bioavailability of 5-FU to 100% facilitating uniform absorption and predictable toxicity.(In Vivo):Eniluracil (5-Ethynyluracil) (1 mg/kg; i.p.; single daily for 3 days) exhibits neither toxicity nor intrinsic antitumor activity, and greatly improves FUra (5-fluorouracil) therapy in rats.

——

Eniluracil (5-Ethynyluracil) (1 mg/kg; i.p.; single daily for 3 days) exhibits neither toxicity nor intrinsic antitumor activity, and greatly improves FUra (5-fluorouracil) therapy in rats. Animal Model:Female Fischer 344/HSD rats (6 to 7-week-old; 150-200 g).Dosage:1 mg/kg Administration:Intraperitoneal injection; single daily for 3 days (l h before FUra (5-fluorouracil) and for an additional 2 days after FUra therapy)Result:Produced complete tumor regression that was sustained for at least 90 days posttherapy when combined with 3.5 mg/kg FUra, however, 35 mg/kg FUra alone produced partial responses in 75% of the treated animals ( the tumors regrew in all of these animals).

5-Ethynyluracil | GW776C85

Others

Other Targets

dihydropyrimidine dehydrogenase (DPD)

Cancer

Colorectal Cancer; Erythrodysaesthesia; Head and neck Cancer; Liver Cancer; Pancreatic Cancer; Prostate Cancer; Solid tumours

59989-18-3

136.11

C6H4N2O2

>98% (HPLC)

DMSO:62.5 mg/mL (459.19 mM)

C#Cc1c[nH]c(=O)[nH]c1=O

5-ethynylpyrimidine-24(1H3H)-dione.

(-20℃)

With Ice Pack

≥ 2 years